Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study
复制标题
利培酮与氟哌啶醇治疗慢性精神分裂症住院患者：一项多中心双盲比较研究
DOI：
--
复制
发表时间：
1992
影响因子：
6.7
通讯作者：
S. Heylen
中科院分区：
文献类型：
--
作者：
A. Claus;J. Bollen;H. D. Cuyper;M. Eneman;M. Malfroid;J. Peuskens;S. Heylen
44例慢性精神分裂症住院患者参加了这项为期12周的多中心、平行分组、双盲试验。经过2周的磨合期和1周的单盲安慰剂冲洗后，他们被随机分配到5-羟色胺2和多巴胺-D2拮抗剂利培酮或氟哌啶醇治疗。两名患者被排除在疗效分析之外。氟哌啶醇组有5名患者退出，利培酮组有1名患者退出。试验结束时，利培酮的平均日剂量为12毫克，氟哌啶醇为10毫克。利培酮组在精神分裂症阳性和阴性症状量表、情感障碍及精神分裂症改变量表、住院病人护士观察量表等方面均有较大改善。利培酮组的阴性症状改善更明显，直到双盲治疗第8周。与利培酮相比，抗帕金森病药物的消耗量减少了10倍。两种药物耐受性良好，实验室、内分泌和心血管安全参数具有可比性。这项研究表明，利培酮作为一种抗精神病药物与氟哌啶醇相当，但它的EPS图谱更安全。
Forty‐four chronic schizophrenic inpatients participated in this multicentre 12‐week parallel‐group double‐blind trial. After a run‐in period of 2 weeks and a single‐blind placebo wash‐out of 1 week, they were randomly assigned to treatment with either the serotonin2 and dopamine‐D2 antagonist risperidone or haloperidol. Two patients were excluded from the efficacy analysis. Five patients dropped out in the haloperidol group and 1 in the risperidone group. At the end of the trial, the mean daily dose was 12 mg for risperidone and 10 mg for haloperidol. The risperidone group showed greater improvement on the Positive and Negative Syndrome Scale for Schizophrenia, the Schedule for Affective Disorders and Schizophrenia – change version, and the Nurses’ Observation Scale for Inpatient Evaluation. The improvement of negative symptoms was more pronounced in the risperidone group until week 8 of double‐blind treatment. The consumption of antiparkinsonian medication was 10 times lower with risperidone. Both drugs were well tolerated and the laboratory, endocrinological and cardiovascular safety parameters were comparable. This study suggests that risperidone is comparable to haloperidol as an antipsychotic, but that it has a safer EPS profile.
预后极差的精神分裂症的特征。
DOI：
10.1176/ajp.144.7.889
发表时间：
1987
期刊：
The American journal of psychiatry
影响因子：
--
作者：
Keefe,RS;Mohs,RC;Losonczy,MF;Davidson,M;Silverman,JM;Kendler,KS;Horvath,TB;Nora,R;Davis,KL
通讯作者：
Davis,KL